Nebulized Dexmedetomidine and Nebulized Lidocaine in children undergoing fiberoptic bronchoscopy

Comparing the hemodynamic effects of nebulized Dexmedetomidine and nebulized Lidocaine in children undergoing fiberoptic bronchoscopy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160301026866N9

Enrollment

Registered

2018-10-06

Start date

2018-09-11

Completion date

Unknown

Last updated

2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Broncoscopy.

Interventions

Intervention 1: Intervention group 1:will receive premedication with 2 µg/kg of nebulized Dexmedetomidine by recovery nurse. Intervention 2: Intervention group 2: will receive premedication with nebu

Eligibility

Sex/Gender

All

Age

1 Years to 6 Years

Inclusion criteria

Inclusion criteria: Age between 1 and 6 years, Candid for fibropetic bronchoscopy, ASAI,ASAII, Satisfaction to enter the study

Exclusion criteria

Exclusion criteria: The non-entry criteria are having any diagnosed cardiac or liver diseases, having a fever, existence of crackle or ronchi when hearing the lungs, intubation, and using other anesthetics or sedative drugs before the bronchoscopy

Design outcomes

Primary

Measure	Time frame
Hemodynamic effects. Timepoint: 5,10,15,20 minutes after bronchoscopy. Method of measurement: Anesthetic monitoring device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Shafa

Esfahan University of Medical Sciences

shafa_amir@yahoo.com+98 31 3773 5509

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026